Pharvaris (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan Sells 29,070 Shares

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 29,070 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.32, for a total value of $881,402.40. Following the completion of the transaction, the director directly owned 355,167 shares of the company’s stock, valued at approximately $10,768,663.44. This trade represents a 7.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The shares were sold at an average price of $30.07, for a total value of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,350.00.

Pharvaris Trading Down 5.1%

Pharvaris stock traded down $1.57 during trading hours on Friday, hitting $29.44. The stock had a trading volume of 512,191 shares, compared to its average volume of 245,049. The company has a 50-day moving average of $27.62 and a two-hundred day moving average of $26.03. Pharvaris N.V. has a fifty-two week low of $14.59 and a fifty-two week high of $31.14.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.15). As a group, equities analysts forecast that Pharvaris N.V. will post -3.19 EPS for the current year.

Hedge Funds Weigh In On Pharvaris

Hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new position in shares of Pharvaris in the 4th quarter worth approximately $35,000. JPMorgan Chase & Co. raised its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Pharvaris in the 3rd quarter worth approximately $75,000. Barclays PLC acquired a new position in shares of Pharvaris in the 4th quarter worth approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Pharvaris in the 4th quarter worth approximately $86,000.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Wolfe Research assumed coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price for the company. Wall Street Zen cut Pharvaris from a “sell” rating to a “strong sell” rating in a report on Monday, April 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.73.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.